Dogwood Therapeutics, Inc. DWTX
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) is a pain/anesthesia drug developer. Its lead program, Halneuron (tetrodotoxin, Nav1.7 modulator), is in Phase 2 for Chemotherapy-induced neuropathic pain (CINP). Its next catalyst on record is SP16: Start of Phase 1b patient dosing in CIPN (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SP16 — Start of Phase 1b patient dosing in CIPN (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Halneuron (HAL-CINP-203) | Chemotherapy-induced neuropathic pain | small molecule | Phase 2 |
| SP16 (IV) | Chemotherapy-induced peripheral neuropathy (CIPN) | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 pain/anesthesia companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.